Business Context and Reporting Period
Hercules Capital, Inc. (HTGC) is an internally managed, non-diversified closed-end investment company regulated as a Business Development Company (BDC) and taxed as a Regulated Investment Company (RIC). The company focuses on providing senior secured loans to high-growth, venture capital-backed companies in technology and life sciences sectors. This summary covers the quarterly period ended June 30, 2025.
Key Financial Metrics
| Metric | Q2 2025 (Three Months) | YTD 2025 (Six Months) | YTD 2024 (Six Months) |
|---|---|---|---|
| Total Investment Income | $137.5 million | $257.0 million | $246.6 million |
| Net Investment Income | $88.7 million | $166.2 million | $161.5 million |
| Net Realized Gain (Loss) | ($57.6 million) | ($59.2 million) | $2.4 million |
| Net Change in Unrealized Appreciation (Depreciation) | $47.8 million | $22.2 million | ($31.1 million) |
| Net Increase in Net Assets from Operations | $78.9 million | $129.2 million | $132.8 million |
| Net Asset Value (NAV) per Share | $11.84 | $11.84 | $11.43 |
| Total Debt Outstanding | $2.095 billion | $2.095 billion | $1.783 billion |
| Weighted Average Cost of Debt | 5.0% | 4.9% | 5.0% |
| Portfolio Turnover Rate (YTD) | 12.48% | 12.48% | 13.73% |
Material Changes vs. Prior Period
- Investment Income Growth: Total investment income increased 10.0% year-over-year for the six months ended June 30, 2025, driven primarily by a higher weighted average principal outstanding, partially offset by a lower core yield (12.5% vs. 13.7% in the prior year).
- Realized Losses: The company recognized a net realized loss of $59.2 million for the six months ended June 30, 2025, compared to a net realized gain of $2.4 million in the prior year. This was primarily due to write-offs of debt investments (Khoros, LLC and Annex Cloud) and warrant investments (bluebird bio, Inc., AmplifyBio, LLC), as well as foreign exchange losses.
- Unrealized Appreciation: Net unrealized appreciation of $22.2 million for the six months ended June 30, 2025, reversed a depreciation of $31.1 million in the prior year. This shift was largely driven by the reversal of previously recorded unrealized depreciation upon realization events.
- Debt Expansion: Total debt outstanding increased by approximately $312 million year-over-year. The company issued $287.5 million in 2028 Convertible Notes and $350.0 million in June 2030 Notes, while fully repaying $170 million in maturing notes (February, June, and June 3-Year Notes).
- Portfolio Composition: The Software sector grew to 35.2% of the total portfolio, while Drug Discovery & Development decreased to 24.8%. The weighted average investment grading remained stable at 2.26.
Guidance, Outlook, and Risks
- Capital Deployment: The company originated $1.58 billion in net total investment commitments for the six months ended June 30, 2025, with $966.7 million in net debt fundings. Unfunded commitments totaled $471.5 million.
- Liquidity: As of June 30, 2025, available liquidity was approximately $785.6 million, including cash and available borrowing capacity under credit facilities (SMBC and MUFG). The company maintains an asset coverage ratio of 222.2% (excluding SBA debentures).
- Distributions: The Board declared a total distribution of $0.47 per share for the quarter (Base $0.40 + Supplemental $0.07). For the six months ended June 30, 2025, total distributions declared were $0.94 per share.
- Risks:
- Concentration Risk: Six portfolio companies represent greater than 5% of net assets, including Marathon Health, Phathom Pharmaceuticals, and ChenMed.
- Interest Rate Sensitivity: While 97.8% of the debt portfolio has floating rates with floors, rising rates increase the cost of floating-rate debt borrowings (Credit Facilities).
- Valuation Uncertainty: Approximately 97.5% of assets are valued using Level 3 inputs (unobservable), making fair value estimates sensitive to changes in hypothetical market yields and credit spreads.
Investor Verification Checklist
- Verify the specific portfolio companies responsible for the $59.2 million net realized loss (Khoros, Annex Cloud, bluebird bio) and assess the likelihood of future write-offs in the biotech and software sectors.
- Confirm the utilization rates and interest rate floors on the SMBC and MUFG credit facilities to understand the impact of potential rate hikes on net investment income.
- Review the "Core Yield" metric (12.5%) versus the "Effective Yield" (13.9%) to understand the sustainability of income excluding one-time fee accelerations.
- Monitor the status of the $471.5 million in unfunded commitments and the timeline for deployment, particularly given the current macroeconomic environment.
- Check the asset coverage ratio (222.2%) against the 150% regulatory minimum to ensure continued compliance with BDC leverage requirements.